Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, parallel, open-label, 3-arm study to investigate the pharmacokinetic (PK) parameters of amcenestrant in female participants aged 40 to 75 years with mild and moderate hepatic impairment, and in matched participants with normal hepatic function.

Clinical Trial Description

The total study duration from screening period is approximately 41 days. ;

Study Design

NCT number NCT05126329
Study type Interventional
Source Sanofi
Contact Trial Transparency email recommended (Toll free number for US &
Phone 800-633-1610
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date December 15, 2021
Completion date November 30, 2022